Feasibility of point of care testing for prevention and management of breast cancer therapy associated comorbidities in 6 African countries: short communication

Objective: Obesity and mediators of inflammation have been identified as the most important risk and predictive factors in postmenopausal breast cancer (BC) survivors using aromatase inhibitors (AIs). This study was conducted to assess the impact of point of care technology (PCOT) as part of patholo...

Full description

Saved in:
Bibliographic Details
Published in:BMC research notes Vol. 15; no. 1; pp. 1 - 5
Main Authors: Milambo, Jean Paul Muambngu, Ndirangu, James, Nyasulu, Peter S, Akudugu, John M
Format: Journal Article
Language:English
Published: London BioMed Central 22.10.2022
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
Adverse and side effects
Adverse events
Aromatase
Aromatase inhibitors
Biomedical and Life Sciences
Biomedicine
Body fat
Body mass index
Breast cancer
C-reactive protein
Cancer therapies
Cardiovascular risk factors
Care and treatment
Comorbidity
Diagnosis
Drugs
Estrogens
Ferritin
Genetic screening
Genetic testing
Homocysteine
Inflammation
Laboratories
Life Sciences
Lifestyles
Medical diagnosis
Medical screening
Medicine/Public Health
Obesity
Pathology
Patients
Point of care testing
Post-menopause
Postmenopausal breast cancer
Research Note
Risk factors
Statistical analysis
Womens health
South Africa
Africa
Cardiovascular risk factors
Point of care testing
Postmenopausal breast cancer
Aromatase inhibitors
ISSN:1756-0500, 1756-0500
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Obesity and mediators of inflammation have been identified as the most important risk and predictive factors in postmenopausal breast cancer (BC) survivors using aromatase inhibitors (AIs). This study was conducted to assess the impact of point of care technology (PCOT) as part of pathology supported genetic testing (PSGT) to prevent BC therapy-associated comorbidities in African settings. Results The study revealed that high sensitivity C-reactive protein (hs-CRP) and body mass index (BMI) are predictors of cardiovascular (CVD) related adverse events in obese postmenopausal patients subjected to AIs. There were statistically significant variations in total body fat (TBF), weight, hs-CRP, body mass index (BMI), homocysteine, ferritin, and calcium between baseline and after 24 months of follow-up. The above inflammatory markers can be incorporated in pathology supported genetic testing (PSGT) using HyBeacon® probe technology at POC for prediction and management of AI-associated adverse events among postmenopausal breast cancer survivors and associated comorbidities. The barriers for implementation of POCT application among six African countries for diagnosis of breast cancer were documented as insufficient of BC diagnosis and management capacity at different levels of health system.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1756-0500
1756-0500
DOI:10.1186/s13104-022-06204-y